NY-ROHATYN-GROUP
20.11.2014 13:02:25 CET | Business Wire | Pressemeddelelse
The Rohatyn Group (“TRG”), an independent investment firm focused on emerging markets, today announced that TRG Growth Fund II has finalised the sale of its 36.6% shareholding in Huvepharma AD to Advance Properties OOD, a company controlled by the Domuschiev family. Huvepharma AD, headquartered in Sofia, Bulgaria, is a global fully integrated pharmaceutical company focused on developing, manufacturing and marketing animal health and nutrition products, as well as several key ingredients used in human health products. As a result of this transaction, Advance Properties OOD effectively controls 100% of Huvepharma AD.
Kiril Domuschiev, President of Huvepharma, stated: “TRG has been a strong partner for Huvepharma and we are pleased with their contribution to the rapid international development and growth of the company. We are excited that Advance Properties again holds a 100% controlling interest of Huvepharma and continues to support the company in the pursuit of further growth strategies. The combination of an experienced management team and staff and continued investment in product development and global production facilities gives us full confidence that Huvepharma is well placed to sustain an ambitious growth path.”
Sobhi Hatem, Managing Director of TRG, stated: “We are very proud of the successful investment in Huvepharma, which allowed TRG Growth Fund II to capitalise on the growth of one of the most attractive segments of the pharmaceuticals market. The growth that the company has achieved during our partnership period is a testament to our strong collaboration with Advance Properties, particularly with respect to the maximization of our complimentary international footprints. We are confident that the high quality management team that leads Huvepharma will continue to drive future success.”
TRG, along with its subsidiaries and affiliates, has over $5 billion in private emerging markets assets under management, in addition to almost $1 billion in liquid emerging market strategies. TRG last year acquired Citi Venture Capital International (“CVCI”), the emerging market private equity investment unit formerly owned by Citigroup Inc., which expanded and enhanced the firm’s emerging markets investment capabilities and global reach.
Huvepharma AD, which was founded in 2000 by the Domuschiev family, has worldwide operations with 99% of its production sold outside of Bulgaria in more than 95 countries. Huvepharma’s key product categories are feed additives and veterinary products for food producing animals and active human pharmaceutical ingredients. For more information, please visit www.huvepharma.com .
About Advance Properties OOD
Advance Properties OOD is an investment holding company founded and controlled by Bulgarian entrepreneurs Kiril and Georgi Domuschiev. The company owns strategic shares in a well diversified portfolio of companies.
In addition to Huvepharma AD, Advance Properties’ investments include a 70% stake in Navigation Maritime Bulgare (Navibulgar), a Bulgarian shipping company, and other companies in the port operations services, real estate, logistics and manufacturing industries.
The financial strength and flexibility of Advance Properties OOD’s structure is reflected in its ability to provide strategic advice and enhance the effectiveness of management processes and the development of new markets, technologies and products across investments. The investee companies share a strong commitment to integrity, product quality and customer satisfaction.
About TRG
Founded in 2002, The Rohatyn Group is a leading emerging markets asset management firm headquartered in New York, with offices around the globe including, Singapore, Hong Kong, London, Buenos Aires, Lima, Montevideo, Mexico City, São Paulo, Mumbai and New Delhi. For more information, please visit www.rohatyngroup.com .
Contact:
Media
For TRG:
Paul Caminiti/Chris Kittredge/Brian
Shiver, 212-687-8080
Sard Verbinnen & Co
or
For
Advance Properties OOD:
Yavor Iliev, +359 2 8625331
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 22:05:00 CEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
SES Announces Results of the Extraordinary General Meeting of Shareholders17.6.2026 19:23:00 CEST | Press release
SES (the “Company”) held an Extraordinary General Meeting (“EGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions. In particular, shareholders approved the cancellation of shares repurchased under the Company’s share buyback program of 2 November 2023, as amended on 2 May 2024, resulting in a corresponding reduction of the Company’s share capital. Shareholders also approved amendments to the Company’s articles of association, including indemnification for Board members and executives, as well as updates relating to the conduct of shareholder meetings. Detailed results on all matters voted on at the EGM will be available on the company’s webpage: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we b
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum